NASDAQ: ALKS

Alkermes (ALKS) Stock Analysis & Forecast

Nov 13 close

$47.03+0.05 (+0.1%)

Gekko Brief

AI summaryNov 9 close

Alkermes reported third-quarter 2026 results this week, with proprietary product sales up 31% year-over-year and earnings surpassing estimates at $0.52 per share against a $0.52 actual versus a -$0.04 estimate, compared with $0.49 per share a year ago. Management highlighted continued investment in its orexin development portfolio spanning sleep, neuropsychiatric and neurological disorders, alongside research presented at the Neuroscience Education Institute Fall Congress covering its psychiatry and sleep portfolios.

Shares closed at $46.17, up 0.6% on the day, sitting above both the 50-day average of $43.68 and the 200-day average of $40.86, with the 50-day above the 200-day. The GekkoIndex reads 50.4, placing the stock in the Neutral zone, down from a five-day change of -2.2. Price sits within 0.9% of Gekko Fair Value at $46.57, essentially in line with that level.

The next earnings date falls on 24 February 2027, 101 days away and outside a typical 20-trading-day holding window. Over the last 90 days, Congressional activity shows 1 buy and 0 sells. Seasonality from this point in the calendar has averaged -3.2% over the next 20 trading days across 5 years, rising in 3 of those years. Analyst coverage from 13 firms includes 9 buy ratings, 3 hold and 1 sell, with a consensus target of $56.21.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Alkermes price vs fair value

$47.03$44.35Nov ’25May ’26Nov ’26
Close $47.03200-day averageGekko Fair Value $44.35

Alkermes quick facts

Market cap
$7.90B
P/E ratio
—
Forward P/E
133.3
EPS, TTM
−$0.01
Revenue, TTM
$1.75B
Profit margin
0%
Dividend yield
—
Beta
0.23
Volume
1.43M avg 1.71M
1-year return
+49.7%
Typical daily move
±3.8%
Typical 20-day move
±6.7%
50-day average
$43.67
200-day average
$41.13
Next earnings
Feb 24 before open
Shares outstanding
168.0M
52-week range
$27.00$55.67

Alkermes swing-trade checklist

Alkermes scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive1 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $47.03 is above the 50-day ($43.67) and 200-day ($41.13) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    49.8, Neutral

    Reading 49.8 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    6.0% above

    Price is 6% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 90 days: Congress 1 buy / 0 sales.

    See smart money
  • Earnings risksupportive

    Reports in 101 days

    Next report Feb 24, 2027, 101 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +4.5% on average

    From this point in the calendar, the next 20 trading days averaged +4.5% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Alkermes stock chart and price history

Alkermes closed at $47.03 on Nov 13, 2026, +49.7% over the past year, inside a 52-week range of $27.00 to $55.67.

Close50-day average200-day averageVolume
Alkermes share price, past year, with 50-day and 200-day moving averages and volume$30$40$50DecJan 2026FebMarAprMayJunJulAugSepOctNov47.03

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+17.3%
3 months
−5.7%
6 months
+25.5%
1 year
+49.7%
The full ALKS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ALKS in Gekko

Follow Alkermes through every session

Put ALKS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track ALKS in GekkoFree for 7 days. No credit card required.

About Alkermes

Alkermes develops and sells pharmaceutical products aimed at treating conditions such as opioid dependence, alcohol dependence, schizophrenia, and bipolar I disorder. It is known for a set of marketed treatments including ARISTADA and ARISTADA INITIO for schizophrenia, VIVITROL for alcohol and opioid dependence, LYBALVI for schizophrenia and bipolar I disorder, and LUMRYZ for cataplexy or excessive daytime sleepiness in pediatric patients. Alongside these, the company continues work on clinical and preclinical candidates targeting neurological disorders.

Beyond its own product line, Alkermes licenses proprietary technology platforms to other firms, allowing them to develop, manufacture, and bring products to market. It also maintains collaboration agreements with several Janssen Pharmaceutica entities. Its work spans patients and partners in the United States, Ireland, and other international markets.

The company was founded in 1987 and is based in Dublin, Ireland. Its shares are listed on the NASDAQ under the ticker ALKS.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
alkermes.com

Alkermes GekkoIndex: the smart money zone

Alkermes’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 49.8, in the Neutral zone, down 1.9 points over five sessions.

010049.8Neutral

Down 1.9 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying49+0.2%+2.6%+10.8%+15.0%
Accumulation232+0.6%+1.5%+2.2%+5.5%
Neutral (current zone)368+0.4%+0.4%+0.3%+3.3%
Distribution51+0.6%+1.3%+4.1%+2.6%
Selling2Too few readings yet

Average ALKS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the ALKS price, zone by zone.Track ALKS in Gekko

Is Alkermes stock overvalued? Gekko Fair Value

Alkermes trades 6.0% above Gekko Fair Value of $44.35, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Alkermes shares are worth, recalculated every trading day.

$44.35

Gekko Fair Value, Nov 14, 2026

6.0% Overvalued

At the end of Aug 2026 the price was 2.8% below the estimate.

Gekko Fair ValueShare price, month end
$44$47Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open ALKS in Gekko

Alkermes insider and Congress trading

No open-market insider purchases were filed for Alkermes, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for ALKS in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every ALKS insider filing, plotted on the chart in Gekko.Open ALKS in Gekko

Congress trades last 90 days

1trade disclosed: 1 purchase and 0 sales.

MemberTypeAmountDisclosed
Gilbert Cisneros
House, CA, purchase
Purchase$1,001 - $15,000Oct 12
traded Sep 29

From congressional disclosures, which report amounts as ranges.

Buybacks

Alkermes has been buying back its own shares.

Bought back, quarter ended Mar 31, 2026
$27.70M
As a share of market cap
0.35%

From company filings.

Hedge funds and billionaires quarter ended Dec 31

0of the funds Gekko tracks hold ALKS.

0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

Alkermes earnings: next date and track record

Alkermes reports on Feb 24, 2027, before the open (101 days away), and beat the EPS estimate in 6 of its last 8 reports.

6 of 8reports beat the EPS estimate
±7.7%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

−6.3%Oct ’24+12.6%Feb ’25+10.5%May ’25+6.8%Jul ’25+5.8%Oct ’25−8.0%Feb ’26+3.4%May ’26−8.3%Jul ’26

Last earnings call, Jul 28, 2026 AI summary

What they said
Alkermes reported Q2 2026 results with CEO Richard Pops delivering his final earnings call before transitioning to Chairman. Key highlights include advancing alixorexton as the leading orexin 2 receptor agonist, demonstrating efficacy in narcolepsy type 1 and type 2 Phase 2 studies with sustained improvements up to nine months. Phase 3 narcolepsy enrollment is on track, ALKS 7290 is enrolling ADHD patients with Phase 1b data expected Q3, and ALKS 4510 targets MS/Parkinson's fatigue.
Guidance
Phase 3 narcolepsy program expected to complete enrollment next year. ALKS 7290 Phase 1b ADHD data expected by end of Q3 2026. ALKS 4510 fatigue Phase 2 initial data anticipated in 2027. Management projects meaningful clinical readouts across multiple programs in H2 2026.
ReportedEPSSurpriseRevenueSurpriseMove
Jul 28, 2026$0.52
est −$0.04
+1,400.0%$496.0M
est $457.4M
+8.4%−8.3%
May 5, 2026$0.38
est −$0.04
+1,050.0%$392.9M
est $363.1M
+8.2%+3.4%
Feb 25, 2026$0.34
est $0.43
−20.9%$384.5M
est $378.9M
+1.5%−8.0%
Oct 28, 2025$0.65
est $0.39
+66.7%$394.2M
est $356.9M
+10.5%+5.8%
Jul 29, 2025$0.52
est $0.41
+26.8%$390.7M
est $354.5M
+10.2%+6.8%
May 1, 2025$0.13
est $0.25
−48.9%$306.5M
est $302.9M
+1.2%+10.5%
Feb 12, 2025$1.05
est $0.76
+38.2%$430.0M
est $379.4M
+13.3%+12.6%
Oct 24, 2024$0.73
est $0.71
+2.8%$378.1M
est $381.4M
−0.8%−6.3%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Alkermes stock forecast and analyst price targets

Analysts’ average 12-month price target for Alkermes is $57.74, +22.8% from the last close, from 13 firms rating the stock in the last 90 days.

$57.74consensus 12-month target, +22.8% from the last close
Low $50High $83
Buy9
Hold3
Sell1

Each firm’s latest rating in the last 90 days: 13 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 4H.C. WainwrightHold, maintained$50+6.3%
Nov 4Bank of America SecuritiesSell, reiterated——
Nov 3H.C. WainwrightHold, maintained$43−8.6%
Nov 3RBC CapitalBuy, reiterated$57+21.2%
Nov 3Wells FargoBuy, maintained$68+44.6%
+0.3%average 20-day move after past Neutral readings
+4.5%average move over the next 20 trading days in the last 5 years
±3.8%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Alkermes seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Alkermes averaged +4.5% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−4.0%2021+12.1%2022+13.4%2023+7.6%2024−3.0%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−1.2%1 of 5
Next 10 trading days−0.4%2 of 5
Next 15 trading days+4.7%4 of 5
Next 20 trading days+4.5%3 of 5
Next 30 trading days+5.2%4 of 5

For scale, ALKS’s typical 20-trading-day move in either direction is about 6.7%.

Alkermes market cap and key statistics

Alkermes’s market cap is $7.90B and revenue of $1.75B over the last twelve months.

Valuation

Market cap
$7.90B
Forward P/E
133.3
EPS, TTM
−$0.01
Gekko Fair Value
$44.35

Trading

Volume
1.43M
Avg volume, 20 days
1.71M
52-week high
$55.67
52-week low
$27.00
Shares outstanding
168.0M

Financials

Revenue, TTM
$1.75B
Profit margin
0%
Return on equity
0%
Quarterly earnings growth, YoY
−81.6%

Risk and income

Beta
0.23
Typical daily move
±3.8%
Typical 20-day move
±6.7%

Alkermes peers

Alkermes’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Alkermes stock FAQ

What is Alkermes’s market cap?

Alkermes’s market cap is $7.90B at the Nov 13, 2026 close of $47.03, with 168.0M shares outstanding.

What is the Alkermes stock forecast?

The consensus analyst 12-month price target for Alkermes is $57.74, +22.8% from the last close. Of the 13 firms that rated the stock in the last 90 days, 9 rate it a buy, 3 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.

Is Alkermes stock overvalued or undervalued?

On Gekko’s estimate Alkermes is overvalued: the Nov 13, 2026 close of $47.03 is 6.0% above Gekko Fair Value of $44.35. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Alkermes report earnings next?

Alkermes is expected to report on Feb 24, 2027, before the market opens (101 days away). Analysts expect earnings of −$0.24 per share on revenue of $461.6M. Alkermes beat the earnings estimate in 6 of its last 8 reports, moving 7.7% on average across the report.

What is Alkermes’s 52-week high and low?

Alkermes’s 52-week high is $55.67 and its 52-week low is $27.00; it closed at $47.03 on Nov 13, 2026, +49.7% over the past year.

Is Alkermes stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, smart money, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Alkermes the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.